Drug Trial Radar · NCT01828099
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
376
Actual
Start
Jul 9, 2013
Primary completion
Jun 24, 2016
Study completion Jan 7, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV, non-squamous non-small cell lung cancer (NSCLC) harboring a confirmed anaplastic lymphoma kinase (ALK) rearrangement, using the Ventana immunohistochemistry (IHC) test.
Conditions
- Non-Small Cell Lung Cancer
Interventions
CeritinibDrug
Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule.
PemetrexedDrug
Pemetrexed was administered at a dose of 500 mg/m\^2 as an intravenous (iv) infusion on Day 1 of each 21-day cycle
CisplatinDrug
Cisplatin was administered by iv infusion at a dose of 75 mg/m\^2 every 21 days for up to 4 cycles.
CarboplatinDrug
Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC)Time frame: From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months
Locations
167 sites in 29 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
La Rioja, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Auckland, Australia
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
Heidelberg, Victoria, Australia
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Recife, Pernambuco, Brazil
Novartis Investigative Site
Rio de Janiero, Rio de Janeiro, Brazil
Novartis Investigative Site
Natal, Rio Grande do Norte, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Itajaí, Santa Catarina, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São José do Rio Preto, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Chongqing, China
Novartis Investigative Site
Chongqing, China
Novartis Investigative Site
Guang Dong Province, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Shanghai, Shanghai Municipality, China
Novartis Investigative Site
Xi’an, Shanxi, China
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Montería, Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Herlev, Denmark
Novartis Investigative Site
Odense C, Denmark
Novartis Investigative Site
Caen, France
Novartis Investigative Site
Grenoble, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Paris, France
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.